FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:80-82 January 5, 2006 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Targeting signal-transduction molecules, especially kinases, is a daunting task. First, these enzymes are often widely distributed in many tissues and contribute to a vast array of cellular processes essential for survival. Second, truly selective inhibitors can be difficult to synthesize because the target enzyme is often structurally similar to others and many such enzymes share substrates such as ATP. Two recent reports by a single group show how one can overcome these hurdles through a combination of serendipity and inventiveness: the researchers used a novel inhibitor of phosphatidylinositol-3'-kinase (PI3K) to treat mouse models of the inflammatory diseases rheumatoid arthritis¹ . . . [Full Text of this Article]

Source Information

From the Division of Rheumatology, Allergy, and Immunology and the University of California at San Diego Clinical Investigation Institute, University of California at San Diego School of Medicine, La Jolla.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.